Similarly, Novo Nordisks weight loss drug has shown promising liver benefits in a new preclinical study, pointing to effects beyond just shedding pounds
Shared decision-making between the patient and their care team is indicated to decide whether to start, continue or discontinue GLP-1 therapy in the setting of a new diagnosis of NAION or in certain risk contexts, considering the individual patient characteristics and clinical scenario, the guidance article authors wrote
People experiencing side effects also report switching their medication at higher rates (31% versus 19%)
Your care provider will teach you how to give yourself the injection and how to combine it with sexual arousal therapy if needed, and youll have regular check-ins to see how youre responding and to make any needed changes
These include skin rash or hives, weak muscles or cramps, itching, vomiting, nausea, headache, leg pain or warm, tender pain in one leg, dizziness and fatigue, frequent urination, feeling super thirsty, fast heart rate, and swelling of the extremities
The SURMOUNT-5 head-to-head trial directly compared Zepbound to Wegovy, with results published in The New England Journal of Medicine: The addition of GIP receptor activation unlocks approximately 6% additional fat loss compared to GLP-1-only medications, while also helping preserve muscle mass better
.png)
